High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
4.41B
+4.37%
0.671
-5.47%
4.01B
+3.07%
0.583
+12.18%
4.21B
+0.86%
0.660
0%
Estimates Revision
The market is revising Upward the revenue expectations for Teva Pharmaceutical Industries Limited (TEVA) for FY2025, with the revenue forecasts being adjusted by 0.38% over the past three months. During the same period, the stock price has changed by 36.16%.
Revenue Estimates for FY2025
Revise Upward
+0.38%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
+1.51%
In Past 3 Month
Stock Price
Go Up
+36.16%
In Past 3 Month
6 Analyst Rating
Wall Street analysts forecast TEVA.N stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TEVA.N is 29.20 USD with a low forecast of 28.00 USD and a high forecast of 32.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 24.590
Low
28.00
Averages
29.20
High
32.00
Current: 24.590
Low
28.00
Averages
29.20
High
32.00
JPMorgan
Chris Schott
Overweight
maintain
$26 -> $28
2025-11-06
Reason
JPMorgan
Chris Schott
Price Target
$26 -> $28
2025-11-06
maintain
Overweight
Reason
JPMorgan analyst Chris Schott raised the firm's price target on Teva to $28 from $26 and keeps an Overweight rating on the shares. The company reported solid Q3 results, the analyst tells investors in a research note.
Goldman Sachs
Matt Dellatorre
Buy
maintain
$25 -> $28
2025-11-06
Reason
Goldman Sachs
Matt Dellatorre
Price Target
$25 -> $28
2025-11-06
maintain
Buy
Reason
Goldman Sachs analyst Matt Dellatorre raised the firm's price target on Teva to $28 from $25 and keeps a Buy rating on the shares.
UBS
Buy
maintain
$23 -> $26
2025-09-24
Reason
UBS
Price Target
$23 -> $26
2025-09-24
maintain
Buy
Reason
UBS raised the firm's price target on Teva to $26 from $23 and keeps a Buy rating on the shares. The stock can continue to see a relief rally as the Austedo IRA price gets revealed by November 30 or earlier, the analyst tells investors in a research note. Payor insights suggest that the potential IRA discount on Austedo could be about 40% off the list price, UBS says.
Piper Sandler
Overweight
downgrade
$30 -> $29
2025-07-29
Reason
Piper Sandler
Price Target
$30 -> $29
2025-07-29
downgrade
Overweight
Reason
Piper Sandler lowered the firm's price target on Teva to $29 from $30 and keeps an Overweight rating on the shares ahead of quarterly results. The firm says performance for biopharma in Q2 and into Q3 thus far has seen marked improvement, in part a function of fears surrounding tariff-related dislocation receding into the background, in part a function of fears regarding pricing-related dislocation also receding into the background, and in part a function of an anticipated more favorable rate environment. With that said, Piper believes that choppy waters, or perceptions thereof, will continue to render profitable bigger caps as something of a safer haven.
UBS
Buy
maintain
$24 -> $23
2025-06-26
Reason
UBS
Price Target
$24 -> $23
2025-06-26
maintain
Buy
Reason
UBS lowered the firm's price target on Teva to $23 from $24 and keeps a Buy rating on the shares. Despite steady execution progress on its mid- and long-term outlook, shares are down 20% year-to-date, and UBS thinks the stock has been penalized more unfairly than most of the rest of biopharma. Teva management has addressed multiple investor concerns by stabilizing U.S. generics, rekindling Austedo growth from a sleeper, proved R&D execution, and solving the Revlimid cliff, the analyst tells investors in a research note.
Evercore ISI
Outperform
initiated
2025-06-21
Reason
Evercore ISI
Price Target
2025-06-21
initiated
Outperform
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Teva Pharmaceutical Industries Ltd (TEVA.N) is 9.65, compared to its 5-year average forward P/E of 4.70. For a more detailed relative valuation and DCF analysis to assess Teva Pharmaceutical Industries Ltd 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
Strongly Overvalued
5Y Average PE
4.70
Current PE
9.65
Overvalued PE
6.27
Undervalued PE
3.13
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
Strongly Overvalued
5Y Average EV/EBITDA
6.90
Current EV/EBITDA
8.79
Overvalued EV/EBITDA
7.42
Undervalued EV/EBITDA
6.38
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
1.07
Current PS
25.41
Overvalued PS
3.37
Undervalued PS
-1.23
Financials
Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
TEVA.N News & Events
Events Timeline
(ET)
2025-11-07
18:03:35
Teva Pharma: Austedo and Austedo XR Show Beneficial Real-World Effects
2025-11-05 (ET)
2025-11-05
10:00:07
Teva's Stock Increases by 18.3%
2025-11-05
09:04:01
Teva Attributes Generics Struggles to Timing of Launches
Sign Up For More Events
Sign Up For More Events
News
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/ff23dd00fc083d15c8d7c85990813e36c282e00369d0069af9754180a5733ce7.png)
Preview
5.0
11-15BenzingaDruckenmiller Invests in Amazon and Exits Microsoft — A Look at Duquesne's Key Q3 Transactions
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/5b596acec4d82349337820aa1fff34f8666f1a3546b3c0582ecd97241a6c7d21.jpeg)
Preview
5.0
11-15SeekingAlphaGlenview invests in Pinterest and Zillow, divests from Wayfair and ON in Q3 activities.
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/0ed627587b59ba0b3eab09a080a5fbd5d7fedb16ff16fe4c4f20de5dfd33ebd5.png)
Preview
2.0
11-09BenzingaExpedia, Sandisk, and Penumbra Rank Among the Top 10 Large-Cap Winners Last Week (Nov. 3-Nov. 7): Is Your Portfolio Included?
Sign Up For More News
People Also Watch
FAQ
What is Teva Pharmaceutical Industries Ltd (TEVA.N) stock price today?
What is Teva Pharmaceutical Industries Ltd (TEVA.N)'s business?
What is the price predicton of TEVA.N Stock?
What is Teva Pharmaceutical Industries Ltd (TEVA.N)'s revenue for the last quarter?
What is Teva Pharmaceutical Industries Ltd (TEVA.N)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Teva Pharmaceutical Industries Ltd (TEVA.N)'s fundamentals?
How many employees does Teva Pharmaceutical Industries Ltd (TEVA.N). have?